Drug Delivery and Translational Research ( IF 5.7 ) Pub Date : 2023-06-10 , DOI: 10.1007/s13346-023-01362-3 Dennis Makafui Dogbey 1 , Valeria Esperanza Sandoval Torres 2 , Emmanuel Fajemisin 1 , Liyabona Mpondo 1 , Takunda Ngwenya 1 , Olusiji Alex Akinrinmade 1 , Adam W Perriman 2 , Stefan Barth 1, 3
|
The burden of cancer is increasing globally. Several challenges facing its mainstream treatment approaches have formed the basis for the development of targeted delivery systems to carry and distribute anti-cancer payloads to their defined targets. This site-specific delivery of drug molecules and gene payloads to selectively target druggable biomarkers aimed at inducing cell death while sparing normal cells is the principal goal for cancer therapy. An important advantage of a delivery vector either viral or non-viral is the cumulative ability to penetrate the haphazardly arranged and immunosuppressive tumour microenvironment of solid tumours and or withstand antibody-mediated immune response. Biotechnological approaches incorporating rational protein engineering for the development of targeted delivery systems which may serve as vehicles for packaging and distribution of anti-cancer agents to selectively target and kill cancer cells are highly desired. Over the years, these chemically and genetically modified delivery systems have aimed at distribution and selective accumulation of drug molecules at receptor sites resulting in constant maintenance of high drug bioavailability for effective anti-tumour activity. In this review, we highlighted the state-of-the art viral and non-viral drug and gene delivery systems and those under developments focusing on cancer therapy.
Graphical Abstract
中文翻译：
使用病毒和非病毒载体传递遗传和非遗传货物进行癌症治疗的技术进步
全球癌症负担正在增加。其主流治疗方法面临的一些挑战已成为开发靶向递送系统的基础，以将抗癌有效载荷携带和分发到其确定的目标。这种药物分子和基因有效负载的位点特异性递送选择性地靶向可药物生物标志物，旨在诱导细胞死亡，同时不伤害正常细胞，这是癌症治疗的主要目标。病毒或非病毒递送载体的一个重要优点是穿透实体瘤随意排列和免疫抑制的肿瘤微环境和/或抵抗抗体介导的免疫反应的累积能力。非常需要结合合理的蛋白质工程的生物技术方法来开发靶向递送系统，该系统可以作为包装和分配抗癌药物的载体，以选择性地靶向和杀死癌细胞。多年来，这些化学和基因修饰的递送系统旨在药物分子在受体位点的分布和选择性积累，从而持续维持高药物生物利用度，从而实现有效的抗肿瘤活性。在这篇综述中，我们重点介绍了最先进的病毒和非病毒药物和基因传递系统以及正在开发的专注于癌症治疗的系统。
京公网安备 11010802027423号